Company Dossier · Health Care
Bruker
- Russell 1000
- MidCap 400
What Bruker is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $3.50 billion, up 1.7% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.09 billion, up 80% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.10 billion, down 17% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.01 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 4, 2026): sentiment 0.30 on a −1 to +1 scale (mixed), confidence 0.70 of 1.Palanor Discourse
- Guidance in the last 90 days: 1 outlook figure raised, 1 lowered, 3 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 27, 2026): 4 risk factors added, 3 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $0.5 million on the open market.SEC Form 4
- 416 institutional managers reported a position at June 30, 2026 (+71 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 6 (12 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →Company Posture covers S&P 500 companies.
Credit
How these are built →No bond term sheets or tagged debt on file for Bruker yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Bruker: earnings call confidence
Palanor Discourse score per call, 0 to 1
Hiring and ownership
In the news
Headlines that name Bruker, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralBruker Corp (BRKR) Shares Fall 4.3% -- GF Value Says Still Overvalued
gurufocus.com · via Marketaux · Oct 1, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 13, 2026Patent
- Oct 13, 2026Patent
- Oct 6, 2026Patent
- Sep 15, 2026Patent
- Aug 25, 2026PatentPatent granted: OPTOELECTRONIC CHIPUS 12716843
- May 29, 20268-KShareholder vote resultsItem 5.07
- May 21, 20268-KShareholder vote resultsItem 5.07
- Apr 10, 20268-KDirector or officer changeItem 5.02
- Apr 1, 20268-KDirector or officer changeItem 5.02
- Feb 27, 202610-KAnnual report (10-K)4 risk factors added, 3 removed
- Feb 20, 20268-KDirector or officer changeItem 5.02
- Dec 9, 20258-KDirector or officer changeItem 5.02
- May 29, 20258-KDirector or officer changeItem 5.02
- May 29, 20258-KShareholder vote resultsItem 5.07
- Mar 3, 202510-KAnnual report (10-K)4 risk factors added, 0 removed
- Feb 21, 20258-KDirector or officer changeItem 5.02
- Jan 16, 20258-KDirector or officer changeItem 5.02
- Feb 29, 202410-KAnnual report (10-K)0 risk factors added, 1 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Globus Medical GMED | $3.1B | $0.8B | Jun 30, 2026 |
| Insulet Corporation PODD | $3.0B | $0.3B | Jun 30, 2026 |
| Revvity RVTY | $2.9B | $0.6B | Jul 5, 2026 |
| Idexx Laboratories IDXX | $4.5B | $1.3B | Jun 30, 2026 |
| Dexcom DXCM | $5.0B | $1.4B | Jun 30, 2026 |
| Teleflex TFX | $2.3B | $0.2B | Jun 30, 2026 |
| ResMed| RMD | $5.7B | $1.6B | Jun 30, 2026 |
| Steris STE | $6.0B | $0.9B | Jun 30, 2026 |